Form 4: Translate Bio, Inc. (TBIO), Renaud Ronald C JR, transaction 01/14/2021

Summary

Ronald C. Renaud, Jr., director and Chief Executive Officer of Translate Bio, Inc. [TBIO], files this Form 4 for option exercises on 01/14/2021. Table I records 5,638 shares acquired at $7.39 and a further exercise at $8.34, for 494,205 shares of common stock owned directly, along with 409,913 and 40,909 shares owned indirectly through family trusts. After the exercises, Table II shows 1,080,035 options remaining at $7.39, expiring 12/21/2027, and 89,996 at $8.34, expiring 03/06/2028. The footnotes give grant dates of December 22, 2017 and March 7, 2018 and the monthly vesting schedules. The form is signed /s/ Paul Burgess as attorney-in-fact on 01/14/2021.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

SEC Form 4

FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB APPROVAL | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB Number: | 3235-0287 | Estimated average burden | hours per response: | 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person * Renaud Ronald C JR (Last) (First) (Middle) C/O TRANSLATE BIO, INC. 29 HARTWELL AVE (Street) LEXINGTON MA 02421 (City) (State) (Zip) | Renaud Ronald C JR | (Last) | (First) | (Middle) | C/O TRANSLATE BIO, INC. | 29 HARTWELL AVE | LEXINGTON | MA | 02421 | (City) | (State) | (Zip) | 2. Issuer Name and Ticker or Trading Symbol Translate Bio, Inc. [ TBIO ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner X Officer (give title below) Other (specify below) Chief Executive Officer, Pres. | X | Director | 10% Owner | X | Officer (give title below) | Other (specify below) | Chief Executive Officer, Pres.
3. Date of Earliest Transaction
 (Month/Day/Year) 01/14/2021
4. If Amendment, Date of Original Filed
 (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | X | Form filed by One Reporting Person | Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr.
 3) | 2. Transaction Date
 (Month/Day/Year) | 2A. Deemed Execution Date, if any
 (Month/Day/Year) | 3. Transaction Code (Instr.
 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr.
 3, 4 and 5) | 5.
 Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 7. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | Amount | (A) or (D) | Price
Common Stock | 01/14/2021 | M | 5,638 | A | $ 7.39 | 494,204 | D
Common Stock | 01/14/2021 | M | 1 | A | $ 8.34 | 494,205 | D
Common Stock | 409,913 | I | By Ronald Renuad 2014 Irrevocable Family Trust
Common Stock | 40,909 | I | By Ronald C. Renaud, Jr. Trust - 2007
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr.
 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date
 (Month/Day/Year) | 3A. Deemed Execution Date, if any
 (Month/Day/Year) | 4. Transaction Code (Instr.
 8) | 5.
 Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr.
 3, 4 and 5) | 6. Date Exercisable and Expiration Date
 (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr.
 3 and 4) | 8. Price of Derivative Security (Instr.
 5) | 9.
 Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 11. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares
Stock Option (right to buy) | $ 7.39 | 01/14/2021 | M | 5,638 | (1) | 12/21/2027 | Common Stock | 5,638 | $ 0.00 | 1,080,035 | D
Stock Option (right to buy) | $ 8.34 | 01/14/2021 | M | 1 | (2) | 03/06/2028 | Common Stock | 1 | $ 0.00 | 89,996 | D
Explanation of Responses:
1. This option was granted on December 22, 2017. The shares underlying the option are scheduled to vest over four years in equal monthly installments through March 9, 2021.
2. This option was granted on March 7, 2018. The shares underlying the option are scheduled to vest over four years, with 25% of the shares vesting on March 7, 2019 and the remainder vesting in equal monthly installment through March 7, 2022.
Remarks:
/s/ Paul Burgess, as attorney-in-fact for Ronald C. Renaud, Jr. | 01/14/2021
** Signature of Reporting Person | Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction
 4

 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

File and source

File

SEC_TBIO_4_filed2021-01-14_0001209191-21-003697.xml

Size

19,168 bytes

SHA-256

bb36edfc0259d958257e397badab7d829fb98256ddc37f834189b418f543efd3

Our copy

SEC_TBIO_4_filed2021-01-14_0001209191-21-003697.xml

Original

www.sec.gov